FALCON-HD is a Phase 2/3 randomized, double-blind, placebo-controlled, dose ranging study to evaluate the pharmacodynamics, safety, and efficacy of SKY-0515 in participants with Stage 2 and early ...

Skyhawk Therapeutics has dosed the first subject in the randomised Phase II/III FALCON-HD trial of the oral small-molecule RNA splicing modulator, SKY-0515, for Huntington's disease (HD) treatment ...

FALCON-HD is a Phase 2/3 randomized, double-blind, placebo-controlled, dose ranging study to evaluate the pharmacodynamics, safety, and efficacy of SKY-0515 in participants with Stage 2 and early ...